Shilpa Medicare responds to news on US chemotherapy drug recall
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On July 29 2026, Shilpa Medicare voluntarily recalled 27,923 vials of chemotherapy drug Pemetrexed Injection (Pemetri RTU) in the US across 4 batches. The US FDA classified it as a Class II recall due to atypical green discoloration. No adverse events reported. Recall is limited to specific batches and does not affect other products or manufacturing. Company says no material financial or operational impact is expected.
Minor — voluntary Class II recall limited to 4 batches, company says no material impact on finances or operations.